Stifel analyst Alex Thompson reiterated a Buy rating and $120.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).The analyst commented, "Sanofi ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Raymond James on Dianthus Therapeutics (DNTH) Amid 8% Gain: 'Incrementally More Bullish On The CIDP Program (again)'June 12, 2026 2:53 PM Wolfe Research on Dianthus Therapeutics (DNTH): 'Not a negative but also not a strong positive'June 10, 2026 10:40 AM